Small Molecule and Biotechnology-Based Therapeutics for Immunology: 2021 IPO Review Pt. VI
This article is Part VI of a review series covering all the initial public offerings for the biotech and pharmaceutical industries in 2021. Pt. I and Pt. II provided an overview of 2021 IPOs by therapy area, technology, and therapeutic class. Pt. III and Pt. IV provided a deep dive into the 2021 IPOs for oncology-focused companies, while P.t V provided a deep dive into the 2021 IPOs for neurology-focused companies.
This short article takes a deeper look into the 2021 IPOs for small molecule and biotechnology-based therapeutics being developed by immunology-focused companies, including:
S1P1 modulators for inflammatory diseases
An IL-17 antagonist from DEL screening
An immune cell-based therapy
An anti-TL1A antibody